IL112768A - Pharmaceutical compositions containing oncostatin m for inhibiting angiogenesis - Google Patents

Pharmaceutical compositions containing oncostatin m for inhibiting angiogenesis

Info

Publication number
IL112768A
IL112768A IL112768A IL11276890A IL112768A IL 112768 A IL112768 A IL 112768A IL 112768 A IL112768 A IL 112768A IL 11276890 A IL11276890 A IL 11276890A IL 112768 A IL112768 A IL 112768A
Authority
IL
Israel
Prior art keywords
oncostatin
cells
cell
expression
class
Prior art date
Application number
IL112768A
Other languages
English (en)
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/335,399 external-priority patent/US5202116A/en
Application filed by Oncogen filed Critical Oncogen
Publication of IL112768A publication Critical patent/IL112768A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL112768A 1989-04-10 1990-04-09 Pharmaceutical compositions containing oncostatin m for inhibiting angiogenesis IL112768A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/335,399 US5202116A (en) 1989-04-10 1989-04-10 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
US50448690A 1990-04-04 1990-04-04
IL9405590A IL94055A (en) 1989-04-10 1990-04-09 Oncostatin M Container Pharmaceuticals to Change Tissue Immunogenicity and Improve Implant Absorption

Publications (1)

Publication Number Publication Date
IL112768A true IL112768A (en) 1998-06-15

Family

ID=26989684

Family Applications (7)

Application Number Title Priority Date Filing Date
IL112768A IL112768A (en) 1989-04-10 1990-04-09 Pharmaceutical compositions containing oncostatin m for inhibiting angiogenesis
IL9405590A IL94055A (en) 1989-04-10 1990-04-09 Oncostatin M Container Pharmaceuticals to Change Tissue Immunogenicity and Improve Implant Absorption
IL11276690A IL112766A (en) 1989-04-10 1990-04-09 Pharmaceutical preparations containing oncostatin M intended for increased fibrinolysis and thrombolysis
IL112767A IL112767A (en) 1989-04-10 1990-04-09 Pharmaceutical compositions containing oncostatin m
IL11276695A IL112766A0 (en) 1989-04-10 1995-02-23 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
IL11276895A IL112768A0 (en) 1989-04-10 1995-02-23 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
IL11276795A IL112767A0 (en) 1989-04-10 1995-02-23 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m

Family Applications After (6)

Application Number Title Priority Date Filing Date
IL9405590A IL94055A (en) 1989-04-10 1990-04-09 Oncostatin M Container Pharmaceuticals to Change Tissue Immunogenicity and Improve Implant Absorption
IL11276690A IL112766A (en) 1989-04-10 1990-04-09 Pharmaceutical preparations containing oncostatin M intended for increased fibrinolysis and thrombolysis
IL112767A IL112767A (en) 1989-04-10 1990-04-09 Pharmaceutical compositions containing oncostatin m
IL11276695A IL112766A0 (en) 1989-04-10 1995-02-23 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
IL11276895A IL112768A0 (en) 1989-04-10 1995-02-23 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
IL11276795A IL112767A0 (en) 1989-04-10 1995-02-23 Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m

Country Status (10)

Country Link
EP (1) EP0422186B1 (xx)
JP (4) JPH04502769A (xx)
AT (1) ATE174223T1 (xx)
CA (1) CA2028825A1 (xx)
DE (1) DE69032816T2 (xx)
DK (1) DK0422186T3 (xx)
ES (1) ES2124690T3 (xx)
GR (6) GR1002178B (xx)
IL (7) IL112768A (xx)
WO (1) WO1990012585A1 (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
CA2055122A1 (en) * 1990-11-13 1992-05-14 Robert I. Grove Methods for stimulating ldl uptake and ldl receptor expression
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
AU3737893A (en) * 1992-03-05 1993-10-05 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5241051A (en) * 1992-04-24 1993-08-31 Research Development Foundation Oncoinhibin
JP3490443B2 (ja) * 1992-10-29 2004-01-26 ジ・オーストラリアン・ナショナル・ユニバーシティ 血管形成阻害性抗体
EP0602290B1 (en) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
KR20010042288A (ko) 1998-03-31 2001-05-25 블레어 큐. 퍼거슨 신생혈관 형성 질환의 영상화용 약제
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
EP1140204A2 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
EP1140864A2 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
AU2003295401B2 (en) * 2002-11-08 2010-04-29 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
ES2342529B1 (es) 2008-10-07 2011-05-11 Proyecto De Biomedicina Cima, S.L. Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6463395A (en) * 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity

Also Published As

Publication number Publication date
DK0422186T3 (da) 1999-08-16
ES2124690T3 (es) 1999-02-16
IL112767A0 (en) 1995-05-26
GR900100278A (en) 1991-09-27
GR920100459A (el) 1994-03-31
JPH1028595A (ja) 1998-02-03
IL94055A0 (en) 1991-01-31
GR1002182B (en) 1996-04-30
GR1002178B (en) 1996-04-30
GR920100458A (el) 1994-03-31
ATE174223T1 (de) 1998-12-15
GR920100455A (el) 1994-03-31
IL112766A0 (en) 1995-05-26
JPH04502769A (ja) 1992-05-21
GR920100457A (el) 1994-03-31
IL112766A (en) 1996-06-18
GR1002187B (en) 1996-04-30
WO1990012585A1 (en) 1990-11-01
JPH1029948A (ja) 1998-02-03
GR1000968B (el) 1993-03-16
CA2028825A1 (en) 1990-10-11
GR920100456A (el) 1994-03-31
DE69032816D1 (de) 1999-01-21
EP0422186A4 (en) 1993-09-15
IL112768A0 (en) 1995-05-26
IL94055A (en) 1995-11-27
GR1002186B (en) 1996-04-30
IL112767A (en) 1998-01-04
JPH1029949A (ja) 1998-02-03
GR1002185B (en) 1996-04-30
EP0422186A1 (en) 1991-04-17
DE69032816T2 (de) 1999-07-29
EP0422186B1 (en) 1998-12-09

Similar Documents

Publication Publication Date Title
IL112768A (en) Pharmaceutical compositions containing oncostatin m for inhibiting angiogenesis
Seckinger et al. A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha.
Roux-Lombard et al. Production of interleukin-1 (IL-1) and a specific IL-1 inhibitor during human monocyte-macrophage differentiation: influence of GM-CSF
Cooper et al. IL-1 activity is reduced in psoriatic skin. Decreased IL-1 alpha and increased nonfunctional IL-1 beta.
Libby et al. Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells.
Mortensen et al. Interaction of recombinant IL-1 and recombinant tumor necrosis factor in the induction of mouse acute phase proteins.
CA2557677A1 (en) In vitro test system for predicting patient tolerability of therapeutic agents
US5744442A (en) Regulation of cellular invasiveness
Dauchel et al. Expression of complement alternative pathway proteins by endothelial cells. Differential regulation by interleukin 1 and glucocorticoids
US5202116A (en) Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m
KR20010022887A (ko) 내피의 단백질분해 활성 및/또는 맥관형성 활성의 자극, 조절 및/또는 저해
Ismair et al. Autocrine regulation of matrix metalloproteinase-9 gene expression and secretion by tumor necrosis factor-α (TNF-α) in NB4 leukemic cells: specific involvement of TNF receptor type 1
Hass et al. Regulation of TNF-α, IL-1 and IL-6 synthesis in differentiating human monoblastoid leukemic U937 cells
Peters et al. Release of Soluble Fibronectin Containing an Extra Type III Domain (ED1) during Acute Pulmonary Injury Mediated by Oxidants or Leukocytes in ViV01-4
Zoellner et al. Cytokine regulation of the synthesis of plasminogen activator inhibitor-2 by human vascular endothelial cells
Borish et al. Transthyretin is an inhibitor of monocyte and endothelial cell interleukin-1 production
Christ et al. Type 1 plasminogen activator inhibitor synthesis of endothelial cells is downregulated by smooth muscle cells
Schneider et al. Basement membrane proteins in synovial membrane: distribution in rheumatoid arthritis and synthesis by fibroblast-like cells
Gallicchio et al. Stimulation of PAI-1 expression in endothelial cells by cultured vascular smooth muscle cells.
Hakkert et al. Monocytes enhance the bidirectional release of type I plasminogen activator inhibitor by endothelial cells
Huber et al. Activation of human platelet-derived latent transforming growth factor-β 1 by human glioblastoma cells. Comparison with proteolytic and glycosidic enzymes
Kojima et al. Lipopolysaccharide inhibits activation of latent transforming growth factor‐β in bovine endothelial cells
Brinckerhoff et al. Autocrine control of collagenase synthesis by synovial fibroblasts
AU6191499A (en) Chemokine receptor antagonist and cyclosporin in combined therapy
AU630106B2 (en) Tumor necrosis enhancing factor and methods of preparation and use

Legal Events

Date Code Title Description
FF Patent granted
EXP Patent expired
RH Patent void